NADH Test

Your cells run on a constant back-and-forth exchange of electrons between two forms of the same molecule: NAD+ (the empty carrier, ready to accept electrons) and NADH (the loaded carrier, full of electrons from the food you eat). The balance between these two forms, called the NAD+/NADH ratio, is one of the most fundamental indicators of how your metabolism is performing. When NADH builds up relative to NAD+, it signals that your cells are struggling to process fuel efficiently, a pattern tied to metabolic disease, mitochondrial dysfunction, and accelerated aging.

NADH (nicotinamide adenine dinucleotide, reduced form) is not yet a routine clinical test. No major medical guidelines include it, no standardized reference ranges exist, and the assay technology is still catching up to research demand. But the science connecting this ratio to real health outcomes is growing fast, making NADH a window into metabolic terrain that standard blood panels simply cannot see.

What NADH Actually Tells You

Every time your body breaks down glucose, fats, or amino acids for energy, it loads electrons onto NAD+, converting it to NADH. That NADH then delivers those electrons to your mitochondria (the energy-producing compartments inside your cells), where they drive the production of ATP, your body's universal energy currency. Once NADH hands off its electrons, it reverts to NAD+, ready for another cycle.

When this cycle runs smoothly, the ratio of NAD+ to NADH stays in a range that supports clean energy production and efficient cellular maintenance. When NADH accumulates, either because fuel is flooding in faster than your mitochondria can process it or because mitochondrial function is impaired, the ratio shifts. This shift, sometimes called reductive stress, is the opposite of the oxidative stress most people have heard of. Instead of too many reactive oxygen molecules, reductive stress means too many electrons with nowhere productive to go.

That excess electron pressure can damage the very systems meant to protect your cells. Research on mitochondrial diseases has shown that circulating markers of this NADH-driven reductive stress, including compounds like N-lactoyl-amino acids and certain modified fat molecules, correlate directly with disease severity. The worse the NADH buildup, the more severe the clinical picture.

Metabolic Disease and the NADH Connection

The largest community study examining blood NAD+ levels and metabolic health enrolled 1,394 adults with an average age of 43. The findings were striking and somewhat counterintuitive: people in the highest quarter of whole blood NAD+ levels were roughly 3 times as likely to have metabolic disease as those in the lowest quarter, with an adjusted odds ratio of 3.01. The association grew stronger with more metabolic disease components. Those with three to six components (a combination of high blood pressure, abnormal blood sugar, excess abdominal fat, disordered cholesterol, high uric acid, and fatty liver disease) had more than four times the odds of being in the highest NAD+ quarter compared to the lowest.

This finding may seem paradoxical, since most longevity literature focuses on NAD+ declining with age. But it aligns with the reductive stress model: when cells are overwhelmed with fuel (as in obesity and diabetes), both NAD+ and NADH can rise, but the ratio tips toward NADH dominance. The total NAD pool tells part of the story. The ratio between its oxidized and reduced forms tells a more complete one.

Diabetes and Its Complications

High blood sugar, elevated free fatty acids, and a backup pathway for glucose processing called the polyol pathway all drive NADH accumulation in both the main cell body and the mitochondria. This NADH buildup is not just a bystander. It actively contributes to diabetic complications by generating reactive oxygen species, triggering inflammation-related signaling molecules, and altering how genes are expressed in affected tissues.

Research links this NADH-driven redox imbalance to three of the most serious long-term consequences of diabetes: nerve damage (neuropathy), heart muscle disease (cardiomyopathy), and kidney disease (nephropathy). In the heart specifically, a decreased NAD+/NADH ratio is associated with the metabolic inflexibility seen in diabetic cardiomyopathy, where the heart loses its ability to switch between different fuel sources.

Heart and Vascular Disease

Altered NAD+/NADH ratios have been linked to several cardiovascular conditions, including heart failure, injury from interrupted blood flow (ischemia-reperfusion), irregular heart rhythms, and high blood pressure. A small but informative study comparing 151 healthy blood donors to 19 elderly patients hospitalized for heart failure (ages 75 to 101) found that mean blood NAD concentration was significantly lower in the heart failure group: 20.7 micromoles per liter versus 23.4 micromoles per liter in healthy donors.

This suggests that the total NAD pool may shrink in advanced cardiovascular disease, even as the ratio within that pool may shift toward NADH. The picture is more complex than "more NAD is good, less is bad." Both the total amount and the balance between forms matter.

Mitochondrial Diseases

NADH measurement has the strongest clinical grounding in rare inherited mitochondrial disorders, particularly MELAS (a syndrome involving brain episodes, muscle weakness, and lactic acid buildup) and Leigh syndrome (a progressive brain disease that typically appears in childhood). In these conditions, dysfunctional mitochondria cannot efficiently accept electrons from NADH, causing it to pile up.

A study of patients with the most common MELAS-causing genetic mutation found that a panel of 20 metabolites attributable to NADH reductive stress correlated with disease severity. These markers proved more informative than traditional lactate measurements alone, which have low sensitivity and specificity for mitochondrial disease. In Leigh syndrome, elevated NADH levels in patient cells also correlated with clinical severity. While these are rare conditions, the principle that NADH accumulation signals mitochondrial strain has broader relevance for anyone interested in mitochondrial health.

Age-Related Changes

The NAD+ side of the equation has been studied more extensively in aging than NADH itself. NAD+ levels decline with age across multiple tissues, including liver, skin, muscle, pancreas, and fat tissue. This decline is driven by reduced production of a key recycling enzyme called NAMPT and by increased consumption from DNA-repair enzymes and an immune-related protein called CD38 that becomes more active with chronic inflammation.

One interesting brain imaging study found that while NAD+ decreases in the aging brain, NADH actually increases, suggesting that the ratio shifts progressively toward the reduced form as you age. A study of plasma in adults aged 20 to 87 confirmed that the plasma NAD profile changes with aging, with reduced forms (NADH and NADPH) trending upward. Whether tracking your NADH level over time can serve as an early signal of this aging-related metabolic shift is plausible but unproven.

Chronic Fatigue

A small study measuring serum fluorescence (a method that captures NADH and a related molecule, NADPH) found that people with chronic fatigue syndrome had significantly lower levels than healthy controls: 8.0 versus 10.8 nanomoles per milliliter. Using a cutoff of 9.5 nanomoles per milliliter, the measurement correctly identified 73% of chronic fatigue cases and correctly cleared 100% of healthy controls. While this is a single small study and not a validated diagnostic test, it raises the possibility that NADH measurement could eventually contribute to evaluating unexplained fatigue.

Sex Differences

A German study of 205 adults aged 18 to 83 found that women have higher plasma NAD+/NADH ratios than men, with median ratios of 1.33 versus 1.09. This sex difference diminished with increasing biological age (measured by skin aging markers and arterial stiffness rather than calendar age). A separate fingerstick blood assay study confirmed that males have higher absolute NAD levels than females before age 50. These findings mean that any interpretation of your result should account for your sex and age.

Research-Reported Values

No standardized clinical reference ranges exist for blood NADH. The values below come from research studies using different measurement methods and sample types. They are included to give you a rough sense of the reported range, not as clinical interpretation tiers. Compare your results within the same lab and the same assay over time for the most meaningful signal.

The unit differences across these studies (micromoles per liter in some, nanomoles per milliliter in others) reflect different measurement technologies and sample handling procedures. A meta-analysis of NAD measurement methods across mammalian tissues found substantial variability between and even within methods, making cross-study comparisons unreliable. Your focus should be on your own trend line within a single lab, not on matching your number to a published average from a different assay.

Why a Single Reading Can Fool You

NADH is one of the most technically fragile molecules to measure in blood. Levels can drop by roughly 50% within 24 hours unless samples are specially handled, degassed, and stored under inert gas. The molecule readily converts between its oxidized and reduced forms during sample processing, meaning the number on your report is sensitive to how your blood was drawn, how quickly it was processed, and what extraction method the lab used.

Beyond sample handling, several biological factors can shift your result in ways that do not reflect your true metabolic status. Intense exercise increases muscle NADH from resting levels of about 0.089 millimoles per kilogram to 0.213 millimoles per kilogram at exhaustion, and exercise also changes NAD metabolism in circulating immune cells. Even moderate hemolysis (breakage of red blood cells during the blood draw) can dramatically skew results, because intracellular NAD+ concentrations are roughly 500 times higher than extracellular levels. A slightly rough blood draw can flood the sample with intracellular contents and make the reading meaningless.

NAD+ production is also regulated by your body's internal clock, creating fluctuations throughout the day. For these reasons, draw timing, fasting status, and recent physical activity all matter. Ask your lab about their specific sample handling protocol, and try to keep conditions consistent between draws.

Tracking Your Trend

Given the analytical fragility and biological variability of this measurement, a single reading tells you very little. One study that tracked whole blood NAD+ over 100 days in healthy individuals found that individual baselines were relatively stable under consistent conditions, suggesting that serial measurements within the same lab and assay can reveal a meaningful personal trend.

If you are testing NADH as part of a broader NAD profile, get a baseline under standardized conditions: same time of day, same fasting window, no intense exercise for at least 48 hours before the draw. If you start a new supplement regimen, dietary change, or exercise program aimed at shifting your NAD metabolism, retest in 8 to 12 weeks using the same lab. Then continue with at least annual monitoring. The trajectory of your NAD+/NADH ratio over months and years is far more informative than any single snapshot.

Be clear-eyed about what trending can and cannot tell you with this marker. If you begin taking an NAD+ precursor supplement, studies show these raise whole blood NAD+ or related metabolites, but whether they change your NADH level or your NAD+/NADH ratio in a clinically meaningful way depends on the specific supplement, the dose, and the assay your lab uses. The evidence connecting supplementation to changes in NADH specifically (rather than NAD+ or total NAD) is thin. Track the ratio, not just one side of it.